Blockade of the inhibitory receptor CTLA-4 by mAbs has been tested as a single agent or in combinations in patients with advanced cancer, including breast cancer, lymphoma, melanoma, ovarian cancer, prostate cancer, and ccRCC [9, 15, 17, 51–54]. Here, CTLA4 is linked to prostate carcinoma.